Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Ye Zhao, Nicolas Dzamko
Drugs (2019) Vol. 79, Iss. 10, pp. 1037-1051
Closed Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
Jasmin Galper, Nicholas John Dean, Russell Pickford, et al.
Brain (2022) Vol. 145, Iss. 10, pp. 3472-3487
Open Access | Times Cited: 71
Membrane trafficking in health and disease
Rebecca Yarwood, John Hellicar, Philip Woodman, et al.
Disease Models & Mechanisms (2020) Vol. 13, Iss. 4
Open Access | Times Cited: 120
Preventing Parkinson’s Disease: An Environmental Agenda
Briana R. De Miranda, Samuel M. Goldman, Gary W. Miller, et al.
Journal of Parkinson s Disease (2021) Vol. 12, Iss. 1, pp. 45-68
Open Access | Times Cited: 66
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
Shirley Yin-Yu Pang, Rachel Lo, Philip Wing‐Lok Ho, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena, Tara Richbourg, Claudia P. González-Hunt, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Stem Cell-Based Therapies for Parkinson Disease
Zhaohui Liu, Hoi‐Hung Cheung
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8060-8060
Open Access | Times Cited: 64
Leucine Rich Repeat Kinase 2 and Innate Immunity
Diba Ahmadi Rastegar, Nicolas Dzamko
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 55
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages
Diba Ahmadi Rastegar, Laura P. Hughes, Gayathri Perera, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 30
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease
Kristína Kulcsarová, Corinna Bang, Daniela Berg, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 7, pp. 1079-1106
Open Access | Times Cited: 20
Promising disease-modifying therapies for Parkinson’s disease
Valina L. Dawson, Ted M. Dawson
Science Translational Medicine (2019) Vol. 11, Iss. 520
Open Access | Times Cited: 53
Autophagy and LRRK2 in the Aging Brain
Federica Albanese, Salvatore Novello, Michele Morari
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 50
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Caroline Benn, Lee A. Dawson
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 42
In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson’s Disease in Common Marmosets
Scott Vermilyea, Alexander Babinski, Nina Tran, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 41
Vesicle trafficking and lipid metabolism in synucleinopathy
Saranna Fanning, Dennis J. Selkoe, Ulf Dettmer
Acta Neuropathologica (2020) Vol. 141, Iss. 4, pp. 491-510
Open Access | Times Cited: 35
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
Claudia P. González-Hunt, Elizabeth Thacker, C. M. Toste, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 33
Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
Laura Smith, Chiao‐Yin Lee, Elisa Menozzi, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 21
The emerging role of LRRK2 in tauopathies
Susanne Herbst, Patrick A. Lewis, Huw R. Morris
Clinical Science (2022) Vol. 136, Iss. 13, pp. 1071-1079
Open Access | Times Cited: 19
Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease
Amir Raza, Jeevika Raina, Sanjeev Kumar Sahu, et al.
Neurological Sciences (2025)
Closed Access
Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present)
Xiao Ding, Feng Ren
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 4, pp. 275-286
Closed Access | Times Cited: 32
A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2
Naila Kuhlmann, Austen J. Milnerwood
Frontiers in Molecular Neuroscience (2020) Vol. 13
Open Access | Times Cited: 28
Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate
D.S. Williamson, Garrick P. Smith, Gitte Kobberøe Mikkelsen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 10312-10332
Open Access | Times Cited: 26
LRRK2: Genetic mechanisms vs genetic subtypes
Ignacio Mata, Philippe A. Salles, Mario Cornejo‐Olivas, et al.
Handbook of clinical neurology (2023), pp. 133-154
Closed Access | Times Cited: 9
Applications of oxetanes in drug discovery and medicinal chemistry
G. Huang, Devon G. Hucek, Tomasz Cierpicki, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115802-115802
Open Access | Times Cited: 9
Genetic causes of PD: A pathway to disease modification
Marco Toffoli, Sophia R.L. Vieira, Anthony H.V. Schapira
Neuropharmacology (2020) Vol. 170, pp. 108022-108022
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top